141,119 Shares in Anavex Life Sciences Corp. (NASDAQ:AVXL) Bought by Marshall Wace LLP

Marshall Wace LLP purchased a new position in Anavex Life Sciences Corp. (NASDAQ:AVXL) during the 4th quarter, Holdings Channel.com reports. The firm purchased 141,119 shares of the biotechnology company’s stock, valued at approximately $1,516,000.

Other large investors also recently bought and sold shares of the company. Barclays PLC increased its position in Anavex Life Sciences by 70.4% during the third quarter. Barclays PLC now owns 155,179 shares of the biotechnology company’s stock valued at $882,000 after acquiring an additional 64,101 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new position in Anavex Life Sciences during the 4th quarter valued at about $243,000. Wellington Management Group LLP bought a new position in Anavex Life Sciences during the 4th quarter valued at about $1,704,000. Heartland Advisors Inc. purchased a new stake in Anavex Life Sciences in the 4th quarter worth about $1,674,000. Finally, Virtu Financial LLC purchased a new stake in Anavex Life Sciences in the 4th quarter worth about $967,000. Institutional investors own 31.55% of the company’s stock.

Anavex Life Sciences Price Performance

Anavex Life Sciences stock opened at $9.58 on Tuesday. The firm has a market capitalization of $814.91 million, a P/E ratio of -17.42 and a beta of 0.80. The company’s 50-day moving average is $8.81 and its 200 day moving average is $8.82. Anavex Life Sciences Corp. has a 1-year low of $3.41 and a 1-year high of $14.44.

Anavex Life Sciences (NASDAQ:AVXL) last issued its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03. Research analysts anticipate that Anavex Life Sciences Corp. will post -0.69 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently weighed in on AVXL. HC Wainwright reissued a “buy” rating and issued a $42.00 price objective on shares of Anavex Life Sciences in a research report on Monday, April 7th. D. Boral Capital reissued a “buy” rating and issued a $46.00 price objective on shares of Anavex Life Sciences in a research report on Monday, April 7th.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.